Hyperlipoproteinemia: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 86: Line 86:
|Autosomal Recessive
|Autosomal Recessive
|Normal or '''↑'''
|Normal or '''↑'''
|Normal
|'''↓''' 
|Normal
|'''↓'''  '''↓''' '''↓'''
|'''↑↑↑↑'''
|'''↑↑↑↑'''
|Milky
|Milky
|
|'''↑↑↑↑'''
|
|'''↓''' 
|LPL gene mutation
| -LPL gene mutation
|Chylomicrons
| -Fat tolerance markedly abnormal
 
-Carbohydrate inducibility may be abnormal
Elevated
|Treatment for hyperlipoproteinemia type 1 is intended to control blood triglyceride levels with a very low-fat diet
|Treatment for hyperlipoproteinemia type 1 is intended to control blood triglyceride levels with a very low-fat diet
|<nowiki>-Recurrent Pancreatitis</nowiki>
|<nowiki>-Recurrent Pancreatitis</nowiki>

Revision as of 22:07, 8 November 2016


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Classification

 
 
 
 
 
 
 
 
 
 
 
 
 
Hyperlipoproteinemia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type I:
Familial hyperchylomicronemia
 
 
Type II
 
Type III:
Dysbetalipoproteinemia
 
Type IV:
Primary hypertriglyceridemia
 
Type V:
Mixed hyperlipoproteinemia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type A:
Familial hypercholesterolemia
 
Type B:
Familial combined hyperlipidemia
 

Synopsis

Hyperlipoproteinemia Synonyms Problems Labs description Treatment
Type I Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or familial hyperchylomicronemia Decreased lipoprotein lipase (LPL) or altered ApoC2 Elevated chylomicrons Diet control
Type IIa Polygenic hypercholesterolaemia or familial hypercholesterolemia LDL receptor deficiency Elevated LDL only Bile acid sequestrants, statins, niacin
Type IIb Combined hyperlipidemia Decreased LDL receptor and increased ApoB Elevated LDL, VLDL and triglycerides Statins, niacin, gemfibrozil
Type III Familial Dysbetalipoproteinemia Defect in ApoE synthesis Increased IDL Drug of choice: Gemfibrozil
Type IV Endogenous Hyperlipemia Increased VLDL production and decreased elimination Increased VLDL Drug of choice: Niacin
Type V Familial Hypertriglyceridemia Increased VLDL production and decreased LPL Increased VLDL and chylomicrons Niacin, gemfibrozil

Differential Diagnosis

Diseases Mode of Inheritance Laboratory Findings Other Findings Management Complications Prognosis
Lipid Profile Other Laboratory Findings
Total Cholesterol LDL HDL Triglycerides Plasma Appearance Chylomicrons VLDL Genetic mutations
Primary Hyperlipoprotenemia Type I Autosomal Recessive Normal or       ↑↑↑↑ Milky ↑↑↑↑   -LPL gene mutation -Fat tolerance markedly abnormal

-Carbohydrate inducibility may be abnormal

Treatment for hyperlipoproteinemia type 1 is intended to control blood triglyceride levels with a very low-fat diet -Recurrent Pancreatitis

-Rarely life threatening

Good
Type IIA
Type IIB
Type III
Type IV Autosomal Recessive

&

Autosomal Dominant

Normal or Prebeta-HDL

&

HDL-C

↑↑ Clear or Cloudy Normal -LPL genes (Gly188Glu,Asp9Asn, Asn291Ser,Ser447Ter)

-APOA5

-LMF1

-GPIHBP1

Hyperglycemia, Pancytopneia and pseudo-Niemann

pick cells

-Weight reduction

-Fibrates

-Gene therapy

-Ischemic Heart Disea

-Recurrent Pancreatitis

-NIDDM

-NAFLD

Type V
Secondary Hyperlipoprotenemia Diabetes Mellitus
Alcohol Abuse
Estrogen Therapy
Glucocorticoid therapy
Renal Disease
Obesity
High-fat diet
Poor physical activity
Paraproteinemic disorders
Hypothyroidism


References

Template:WH Template:WS